Cross-border M&A, deal structuring, due diligence, and corporate finance strategies for mid-market and enterprise transactions.
A surge of landmark transactions — from ON Semiconductor’s $7B AI-driven acquisition to Merck KGaA’s $11.3B life sciences deal — is reshaping global M&A strategy in 2025. Decision-makers must prioritize regulatory pre-clearance, rigorous due diligence, and post-merger integration to capitalize on this deal cycle.
Morgan Stanley forecasts global M&A will reach a record $6.4 trillion in 2026, driven by AI-sector consolidation, private equity acceleration, and strong equity markets. CFOs and M&A Directors must act now to navigate intensifying regulatory scrutiny and build integration-ready deal frameworks.
Merck KGaA’s $11.3B acquisition of Bio-Techne and ON Semiconductor’s $7B all-stock deal for Synaptics signal a new wave of capability-driven cross-border M&A in life sciences and AI hardware. Decision-makers should prepare for expanded due diligence scope, longer regulatory timelines, and a sharper focus on post-merger integration discipline.
Merck KGaA’s $11.3B acquisition of Bio-Techne and ON Semiconductor’s $7B Synaptics deal mark a decisive acceleration in cross-border M&A across life sciences and AI infrastructure. For CFOs and M&A Directors, these transactions reveal the strategic logic — and the execution risks — defining corporate finance in 2025.
A wave of cross-border M&A activity exceeding $74 billion — spanning GameStop’s hostile $56B eBay bid, Merck KGaA’s $11.3B life sciences acquisition, and KKR’s energy infrastructure play — signals a structural shift in global deal-making. Decision-makers must act now to align M&A readiness, regulatory strategy, and post-merger integration capabilities.
The SpaceX-xAI acquisition at $1.25 trillion resets the ceiling for global M&A, while cross-border deals in defence, life sciences, and consumer health signal broad strategic repositioning across sectors. Decision-makers must recalibrate due diligence and post-merger integration frameworks to match the pace and complexity of 2026’s deal environment.
Q1 2026 has delivered a structural reset in global M&A activity, led by the historic $1.25 trillion SpaceX–xAI consolidation and significant cross-border deals in life sciences, semiconductors, energy, and defence. For CFOs, General Counsel, and M&A Directors, the emerging deal patterns carry direct implications for regulatory strategy, due diligence frameworks, and post-merger integration planning.
Five transactions exceeding $22 billion in combined value — spanning semiconductors, life sciences, defense, and medical devices — reveal a new phase of strategically disciplined M&A. European acquirers and U.S. targets are converging on AI capability, biologics scale, and defense autonomy as the defining acquisition rationales of 2025.
Five landmark transactions in 2025 — from VodafoneThree’s £-billion telecom merger to Sanofi’s $9.5B precision oncology acquisition — signal a structural acceleration in global M&A activity. Here is what CFOs, General Counsel, and M&A Directors need to understand about the strategic logic, regulatory dynamics, and integration imperatives shaping this cycle.
A 48-hour wave of cross-border deals — including KKR’s $11.3B acquisition of EDF’s North American assets and Elroy Air’s $1B SPAC listing — signals a structural shift in how private equity and venture capital are deploying capital globally. M&A Directors and CFOs must adapt due diligence and post-merger integration frameworks to match the accelerating pace of regulatory approvals in the EU and U.S.